Przewidywanie ciężkości COVID-19 za pomocą swoistego przeciwciała nukleokapsydowego i wskaźnika czynnika ryzyka choroby
Efficient strategies for predicting COVID-19 illness trajectories are urgently wanted. Right here, enzyme-linked immunosorbent assay (ELISA) and coronavirus antigen microarray (COVAM) evaluation mapped antibody epitopes within the plasma of COVID-19 sufferers (n = 86) experiencing a variety of illness states. The experiments recognized antibodies to a 21-residue epitope from nucleocapsid (termed Ep9) related to extreme illness, together with admission to the intensive care unit (ICU), requirement for ventilators, or dying.
Importantly, anti-Ep9 antibodies will be detected inside 6 days post-symptom onset and generally inside 1 day. Moreover, anti-Ep9 antibodies correlate with varied comorbidities and hallmarks of immune hyperactivity. We introduce a simple-to-calculate, illness danger issue rating to quantitate every affected person’s comorbidities and age. For sufferers with anti-Ep9 antibodies, scores above 3.Zero predict extra extreme illness outcomes with a 13.42 probability ratio (96.7% specificity).
The outcomes lay the groundwork for a brand new kind of COVID-19 prognostic to permit early identification and triage of high-risk sufferers. Such data may information simpler therapeutic intervention.IMPORTANCE The COVID-19 pandemic has resulted in over two million deaths worldwide. Regardless of efforts to struggle the virus, the illness continues to overwhelm hospitals with severely ailing sufferers.
Analysis of COVID-19 is quickly completed by means of a mess of dependable testing platforms; nonetheless, prognostic prediction stays elusive. To this finish, we recognized a brief epitope from the SARS-CoV-2 nucleocapsid protein and likewise a illness danger issue rating based mostly upon comorbidities and age. The presence of antibodies particularly binding to this epitope plus a rating cutoff can predict extreme COVID-19 outcomes with 96.7% specificity.
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to Alkaline Phosphatase.
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to Dylight 350.
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to Dylight 405.
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to Dylight 488.
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is unconjugated.
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to ATTO 390.
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to ATTO 488.
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to ATTO 565.
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to ATTO 594.
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to ATTO 633.
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to ATTO 655.
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to ATTO 680.
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to ATTO 700.
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to APC .
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to APC/Cy7.
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to Biotin.
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to Dylight 594.
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to Dylight 633.
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to FITC.
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to HRP.
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to PE/ATTO 594.
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to PerCP.
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to RPE .
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to Streptavidin.
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is unconjugated.
Description: Insulin-like growth factor I (IGF-1) is a polypeptide endocrine hormone structurally similar to insulin and is mainly produced in the liver when stimulated by growth hormone. IGF-1 is a growth factor that stimulates the proliferation of various cell types including muscle, bone, and cartilage tissue
Description: Insulin-like growth factor I (IGF-1) is a polypeptide endocrine hormone structurally similar to insulin and is mainly produced in the liver when stimulated by growth hormone. IGF-1 is a growth factor that stimulates the proliferation of various cell types including muscle, bone, and cartilage tissue
Description: IGF-BPs controls the distribution, function and activity of IGFs in various cell tissues and body fluids. Currently there are seven named IGF-BPs that form high affinity complexes with both IGF-I and IGF-II. IGF-BP1 is a 25.4 kDa cysteine-rich secreted protein expressed in liver, deciduas, and kidneys and is the most abundant IGF-BP in amniotic fluid. Levels of IGF-BP1 in serum are lowest after food. IGF-BP1 binds to both IGF-I and IGF-II with equal affinity. Phosphorylated IGF-BP1 hinders IGF actions, where as nonphosphorylated IGF-BP1 is stimulatory. Recombinant human IGF-BP1 is a 25.4 kDa protein consisting of 235 amino acid residues (Isoform A).
Description: IGF-BP3 is a 30 kDa cysteine-rich secreted protein. It is the major IGF binding protein present in the plasma of human and animals and it is also found in α-granules of platelets. In addition to its ability to modulate the activity of IGF-I and IGF-II, IGF-BP3 exerts inhibitory effects on follicle stimulating hormone (FSH) activity. Decreased plasma levels of IGF-BP3 often results in dwarfism, whereas elevated levels of IGF-BP3 may lead to acromegaly. The expression of IGF-BP3 in fibroblasts is stimulated by mitogenic growth factors such as Bombesin, Vasopressin, PDGF, and EGF. Recombinant human IGF-BP3 is a 28.8 kDa protein consisting of 264 amino acid residues.
Description: IGF-BPs controls the distribution, function and activity of IGFs in various cell tissues and body fluids. Currently there are seven named IGF-BPs that form high affinity complexes with both IGF-I and IGF-II. IGF-BP2 is a cysteine-rich secreted protein produced by bone cells, and is most abundant in the brain. IGF-BP2 has been shown to inhibit IGF-II action in human breast and ovarian carcinoma cells. Recombinant human IGF-BP2 is a 31.5 kDa protein consisting of 289 amino acid residues including the IGF-BP domain and thyroglobulin type-I domain.
*Manufactured using (BTI-Tn-5B1-4) cells under license from the Boyce Thompson Institute for Plant Research, Inc.
Description: IGF-BPs controls the distribution, function and activity of IGFs in various cell tissues and body fluids. IGF-BP6 is produced by bone cells and is the major IGF-BP present in cerebrospinal fluid, and specifically inhibits IGF-II actions. IGF-BP6 has been shown to inhibit IGF-II-dependent cancers such as neuroblastoma, colon cancer and rhabdomyosarcoma. Recombinant human IGF-BP6 has a calculated mass of 22.6 kDa and consists of 213 amino acid residues including the IGF-BP domain and thyroglobulin type-I domain. IGF-BP6 migrates at an apparent molecular weight of approximately 23.0-30.0 kDa by SDS-PAGE analysis under non-reducing conditions.
*Manufactured using (BTI-Tn-5B1-4) cells under license from the Boyce Thompson Institute for Plant Research, Inc.
Description: IGF-BPs controls the distribution, function and activity of IGFs in various cell tissues and body fluids. Currently there are seven named IGF-BPs that form high affinity complexes with both IGF-I and IGF-II. IGF-BP5 is a 28.6 kDa cysteine-rich secreted protein produced by vascular smooth muscle cells. It is the major IGF-binding protein present in bone tissue and helps potentiate the action of IGF-I on smooth muscle cells, fibroblasts or osteoblasts. Data shows that IGFBP-5 acts as a growth inhibitor and pro-apoptotic agent in breast cancer cells. IGFBP-5 overexpressing mice show an increase in neonatal mortality, reduced female fertility, whole-body growth inhibition and retarded muscle development. Recombinant human IGF-BP5 is a 28.6 kDa protein consisting of 253 amino acid residues.
Description: IGF-BPs controls the distribution, function and activity of IGFs in various cell tissues and body fluids. Currently there are seven named IGF-BPs that form high affinity complexes with both IGF-I and IGF-II. IGF-BP7 is expressed in a wide range of normal human tissues and it generally shows reduced expression in cancer cell lines of prostate, breast, colon, and lung origin. It plays a role in skeletal myogenesis by binding to IGF in a manner that inhibits IGF induced differentiation of skeletal myoblasts, without affecting IGF induced proliferation. Additionally, IGF-BP7 suppresses growth and colony formation of prostate and breast cancer cell lines through an IGF independent mechanism, which causes a delay in the G1 phase of the cell cycle, and increased apoptosis. Recombinant human IGF-BP7 is a 26.4 kDa protein consisting of 256 amino acid residues.
Związek między poziomami alarmin w surowicy a wskaźnikami specyficznymi dla choroby u pacjentów z zapaleniem naczyń związanym z cytoplazmatycznymi przeciwciałami przeciw neutrofilom
Background/goal: We evaluated the connection between serum alarmin ranges and disease-specific indices in sufferers with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).
Sufferers and strategies: Sera and knowledge from 79 sufferers have been utilized. For AAV-specific indices, Birmingham vasculitis exercise rating (BVAS), five-factor rating (FFS), and vasculitis harm index (VDI) have been collected and serum ranges of 4 alarmins (hepatoma-derived progress issue, excessive mobility group field protein 1, S100A9, and S100A12) have been measured utilizing enzyme-linked immunosorbent assay. Associations between alarmin ranges, AAV-specific indices, and inflammatory laboratory markers have been assessed.
Outcomes: S100A9 ranges have been considerably correlated with C-reactive protein ranges (r=0.316, p=0.005) and S100A12 ranges correlated with VDI (r=0.232, p=0.040), which was constant in a subgroup of sufferers with myeloperoxidase (perinuclear)-ANCA positivity. No different associations have been discovered between alarmin ranges and BVAS, FFS, and VDI.
Conclusion: The serum S100A12 degree was related to organ harm in AAV, particularly in myeloperoxidase (perinuclear)-ANCA-positive sufferers.
Zapalenie skórno-mięśniowe z dodatnim przeciwciałem anty-MDA5 z szybko postępującą śródmiąższową chorobą płuc: opis dwóch przypadków
Melanoma differentiation-associated protein 5 (MDA5) antibody-positive dermatomyositis (DM) shows distinctive cutaneous and pathologic options. We describe two circumstances of myositis-associated quickly progressive interstitial lung illness (RP-ILD).
The sufferers have been two ladies from Kerala, India. Each sufferers had anti-MDA5 antibody-positive myositis. Each sufferers introduced with RP-ILD with none medical options of myositis and succumbed to their sickness regardless of aggressive medical remedy. Anti-MDA5-antibody-positive DM is characterised by amyopathic illness with quickly progressive and deadly ILD.
Charakterystyka przeciwciał monoklonalnych przeciw tężcowi jako pierwszy krok w kierunku opracowania testu immunologicznego na siłę szczepionki in vitro
Batch launch testing for human and veterinary tetanus vaccines nonetheless depends closely on strategies that contain animals, significantly for efficiency testing. The amount and high quality of tetanus antigen current in these merchandise is of utmost significance for product security and medical impact. Immunochemical strategies that measure consistency of antigen content material and high quality, doubtlessly as an indicator of efficiency, might be a better option and negate the necessity for an in vivo efficiency take a look at. These immunochemical strategies require not less than one nicely characterised monoclonal antibody (mAb) that’s particular for the goal antigen. On this paper we report the outcomes of the great characterisation of a panel of mAbs towards tetanus with a view to pick antibodies that can be utilized for growth of an in vitro efficiency immunoassay.
We’ve got assessed binding of the antibodies to native antigen (toxin), detoxified antigen (toxoid), adsorbed antigen and heat-altered antigen. Antibody perform was decided utilizing an in-house cell-based neutralisation assay to help prior in vivo efficiency knowledge that was accessible for some, however not all, of the antibodies. As well as, antibody affinity was measured, and epitope competitors evaluation was carried out to determine pairs of antibodies that might be deployed in a sandwich immunoassay format. Not all characterisation checks supplied proof of “superiority” of 1 mAb over one other, however collectively the outcomes from all characterisation research allowed for choice of an antibody pair to be taken ahead to assay growth.
Opis przypadku: autoimmunologiczne zapalenie mózgu związane z przeciwciałami dekarboksylazy kwasu przeciwglutaminowego: seria przypadków pediatrycznych
Background: Antibodies towards glutamic acid decarboxylase (GAD) are related to varied neurologic situations described in sufferers, together with stiff particular person syndrome, cerebellar ataxia, refractory epilepsy, and limbic and extralimbic encephalitis. There have been some case experiences and investigations concerning anti-GAD65 antibody-associated encephalitis in grownup populations, however pediatric circumstances are uncommon. We retrospectively analyzed the medical knowledge of three anti-GAD65 antibody-positive sufferers to discover the range and medical options of anti-GAD65 antibody-associated pediatric autoimmune encephalitis.
Strategies: The medical knowledge of a sequence of three sufferers optimistic for anti-GAD65 antibody have been retrospectively analyzed. GAD65 antibodies have been decided in serum and CSF utilizing a cell-based assay.
Outcomes: All three sufferers have been feminine, and the onset ages have been four years and 9 months, 6 years, and 16 years outdated. Their medical phenotypes included autoimmune limbic encephalitis, extralimbic encephalitis, and encephalitis combining limbic and extralimbic encephalitis. The medical signs included seizures, reminiscence deficits, drowsiness, dysautonomia, and headache. All sufferers had irregular carinal MRI and EEG. All sufferers acquired immunotherapy and had transiently good responsiveness, however one affected person then skilled relapse. In follow-up, one affected person with extralimbic encephalitis recovered utterly, whereas two sufferers with limbic involvement had poor outcomes with refractory focal epilepsy.
Conclusion: Along with limbic encephalitis, extralimbic encephalitis can also be an necessary phenotype in sufferers who’re optimistic for anti-GAD65 antibodies. Early analysis and immunotherapy can enhance the signs. Nonetheless, sufferers with limbic encephalitis typically have refractory epilepsy within the power part and have a poor long-term end result.
Description: Human Chemokine (C-X-C motif) Ligand 7 (CXCL7), also known as neutrophil activating peptide 2 (NAP-2), is a member of the CXC chemokines containing an ELR domain (Glu-Leu-Arg tripeptide motif). Similar to other ELR domain containing CXC chemokines, such as IL-8 and the GRO proteins, CXCL7 binds CXCR2, chemoattracts and activates neutrophils. CXCL7, Connective Tissue Activating Protein III (CTAPIII) and beta thrombogulin ( beta TG), are proteolytically processed carboxylterminal fragments of platelet basic protein (PBP) which is found in the alphagranules of human platelets. Although CTAPIII, beta TG, and PBP represent amino-terminal extended variants of NAP2 and possess the same CXC chemokine domains, these proteins do not exhibit CXCL7/NAP2 activity. CXCL7 induces cell migration through the G-protein-linked receptor CXCR-2.
Description: Chemokine (C-X-C motif) ligand 7 (CXCL7), also known as NAP2 or Pro-Platelet basic protein (PPBP), is a human gene. The protein encoded by this gene is a platelet-derived growth factor that belongs to the CXC chemokine family. This growth factor is a potent chemoattractant and activator of neutrophils. It has been shown to stimulate various cellular processes including DNA synthesis, mitosis, glycolysis, intracellular cAMP accumulation, prostaglandin E2 secretion, and synthesis of hyaluronic acid and sulfated glycosaminoglycan. It also stimulates the formation and secretion of plasminogen activator by synovial cells. Furthermore, the protein is an antimicrobial protein with bactericidal and antifungal activity.
Description: A sandwich ELISA kit for quantitative measurement of Mouse ?TG/PBP/CXCL7/NAP2 (Thromboglobulin, Beta) in samples from Serum, Plasma, Cell supernatant
Description: Enzyme-linked immunosorbent assay kit for quantification of Human CXCL7 in samples from serum, plasma, tissue homogenates and other biological fluids.
Description: For the development of sandwich ELISA kit to measure human CXCL7 in cell culture supernates, cell lysates, tissue homogenates, serum and plasma (heparin, EDTA).
Recombinant Rat Neutrophil Activating Protein-2 (CXCL7)
Description: A sandwich ELISA kit for quantitative measurement of Rat ?TG/PBP/CXCL7/NAP2 (Thromboglobulin, Beta) in samples from Serum, Plasma, Cell supernatant
ELISA kit for Human ?TG/PBP/CXCL7/NAP2 (Thromboglobulin, Beta)
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human (Mouse) Cxcl12 . This antibody is tested and proven to work in the following applications:
NAP-2 Neutrophil Activating Protein-2 Rat Recombinant Protein (CXCL7)
Description: NAP-2 Rat Recombinant produced in E.coli is a single, non-glycosylated polypeptide chain containing 62 amino acids and having a molecular mass of 6.8kDa.;The NAP 2 is purified by proprietary chromatographic techniques.
NAP-2 Neutrophil Activating Protein-2 Human Recombinant Protein (CXCL7)
Description: Neutrophil Activating Protein-2 Human Recombinant produced in E.Coli is a non-glycosylated, Polypeptide chain containing 70 amino acids and having a molecular mass of 7609 Dalton. ;The NAP-2 is purified by proprietary chromatographic techniques.
Description: The kit is a sandwich enzyme immunoassay for in vitro quantitative measurement of IP-10/CXCL10 in Mouse serum, plasma and other biological fluids
Description: Enzyme-linked immunosorbent assay kit for quantification of Mouse CXCL16 in samples from serum, plasma, tissue homogenates and other biological fluids.
